LifeStance Health Group Inc. Common Stock Q2 2025 Earnings Recap

LFST Q2 2025 August 8, 2025

Get alerts when LFST reports next quarter

LifeStance Health delivered strong second-quarter performance with 11% revenue growth, achieving double-digit margins and improved clinician productivity, prompting an increase in full-year adjusted EBITDA guidance.

Earnings Per Share Beat

$-0.01 vs $-0.03 est.

+66.7% surprise

Revenue Miss

345311000 vs 358359240 est.

-3.6% surprise

Market Reaction

1-Day +7.93%

5-Day +3.48%

30-Day +8.51%

See LFST alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue grew to $345 million, up 11% year-over-year, driven by a 12% increase in visit volume.
Added 173 clinicians, totaling 7,780, contributing to enhanced service capacity and productivity.
Achieved adjusted EBITDA of $34 million, with margins expected to remain in the double digits for the year.
Implemented a clinician cash incentive program and advanced tech initiatives, including AI solutions to improve operational efficiency.
Strong free cash flow of $57 million, the highest in company history, supports future growth investments.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit LFST on AllInvestView.

Next Q3 2025